However, the discovery of oncogenic driver mutations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) rearrangement, has led to the development of molecular targeted therapy for NSCLC, which in turn has drastically improved patient survival.3, 4. This evidence concerns the gene ALK and non-small cell lung carcinoma.